Announcing the finalists for the 2026 Transatlantic and Foreign Company of the Year Awards
AmCham Denmark, in partnership with the American-Danish Business Council and Copenhagen Capacity, is pleased to announce the finalists for the 2026 Transatlantic Company of the Year and the 2026 Foreign Company of the Year.
These prestigious awards highlight the importance of Danish investments in the United States, and foreign investments in Denmark. The winners will be revealed at the AmCham Business Awards Dinner at Moltkes Palæ on October 1.
Transatlantic Company of the Year
This award celebrates business excellence by a Danish company invested in the United States that demonstrates significant achievements within growth, investments, and/or innovative solutions impacting the U.S. market. Presented in partnership with the American Danish Business Council.
The finalists are:
DSV
DSV is a global leader in transport and logistics, keeping supply chains flowing through integrated air, sea, road, and contract logistics solutions. Combining a worldwide network with local knowledge and deep industry expertise, DSV help businesses navigate complexity, connect markets, and grow. With a strong commitment to operational excellence, innovation, and customer service, they continuously improve the reliability, efficiency, and sustainability of customers’ supply chains, creating long-term value for businesses, people, and society.
Learn more: DSV.com
Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative, and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies, and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.
Learn more: Genmab.com
iMotions
iMotions is a global leader in biometric research software, serving 2,700+ clients across 100+ countries. Founded in Copenhagen and Boston, the company empowers researchers, commercial enterprises, and academic institutions worldwide to analyze human behavior and emotion. Its all-in-one software platform integrates multimodal data, including eye tracking, facial expression analysis, EEG, ECG, and EDA/GSR, enabling users to translate complex physiological responses into actionable insights. By combining Danish innovation with a strong presence across North America and Europe, iMotions is driving global impact and strengthening transatlantic technology collaboration between Denmark and the United States.
Learn more: iMotions.com
Novonesis
Novonesis is leading the era of biosolutions. By leveraging the power of microbiology with science, they transform the way the world produces, consumes and lives. In more than 30 industries around the world, their biosolutions are already creating value for thousands of customers and benefiting the planet. They have 11,000 people worldwide work closely with partners and customers to transform business with biology. Every day, their biosolutions reach more than 2,000,000,000 consumers. Novonesis wants to better the world with biology.
Learn more: Novonesis.com
Foreign Company of the Year
The Foreign Company of the Year is awarded to a foreign company invested into Denmark that demonstrates significant achievements within growth, investments, partnerships and community engagement in Danish society. The award is presented in cooperation with Copenhagen Capacity.
The finalists are:
AstraZeneca
AstraZeneca is a global, science-led, patient focused pharmaceutical company that discovers, develops, and delivers innovative medicines within oncology, biopharmaceuticals, and rare diseases. With a strong commitment to partnerships, sustainability, and patient outcomes, AstraZeneca work closely with the healthcare systems to advance science, improve lives, and help build a more robust and sustainable future for patients and society.
Learn more: AstraZeneca.dk
GE HealthCare
GE HealthCare is a leading global healthcare solutions provider, advancing precision care through innovative medical technologies, pharmaceutical diagnostics, and digital solutions. In Denmark, GE HealthCare combines global expertise with strong local capabilities, including advanced ultrasound technologies from former BK Medical, helping clinicians improve diagnostics, treatment, and patient outcomes. Through continuous innovation, sustainability, and partnership with healthcare providers, they are helping shape a healthier future for patients and communities worldwide.
Learn more: GEHealthCare.com
Medtronic
Medtronic is a leading global healthcare technology company, advancing patient care through innovative medical devices, therapies, and digital health solutions. Guided by its mission to alleviate pain, restore health, and extend life, Medtronic combines global expertise with local collaboration to support healthcare providers and improve outcomes. Through continuous innovation and public-private partnership, the company is helping shape the future of healthcare in Denmark and around the world.
Learn more: Medtronic.com
Each of these companies illustrates something different about the transatlantic relationship: the Danish businesses building scale in the U.S., and the international companies investing in Denmark’s talent, research and communities.
We congratulate all seven finalists and look forward celebrate them and to announcing the winners at the Business Awards Dinner on October 1.